Tonix Pharmaceuticals Holding Corp.
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
About Tonix Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company that commercializes and develops therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. Its commercial product portfolio features TONMYA, a sublingual tablet formulation for treating fibromyalgia in adults, as well as Zembrace SymTouch and Tosymra, both indicated for the treatment of acute migraine. The company's development pipeline encompasses multiple clinical- and preclinical-stage candidates targeting indications such as acute stress disorder, major depressive disorder, organ transplant rejection, cocaine intoxication, and Prader-Willi syndrome.
Tonix markets and distributes its commercial treatments within the United States through internal and contracted sales organizations, digital channels, and national and specialty distributors. The company's principal executive office is situated in Berkeley Heights, New Jersey.
Summary of the business section of Tonix Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tonix Pharmaceuticals Holding Corp.
- Headquarters
- Berkeley Heights, NJ
- Address
- 200 Connell Drive, Suite 3100 07922
- Phone
- (212) 980-9155
- Website
- tonixpharma.com
- Employees
- 142, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- TNXP
- Exchange
- Nasdaq
- IPO date
- May 10, 2012
- Shares outstanding
- 17M, Aug 7, 2026
- Public float
- $271.37M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-100 reverse, Mar 18, 2025; 1-for-100 reverse, Feb 5, 2025; 1-for-32 reverse, Jun 10, 2024; 1-for-31.5 reverse, Aug 8, 2022; 1-for-32 reverse, May 17, 2022; 1-for-10 reverse, Nov 1, 2019; 1-for-10 reverse, Dec 31, 2018; 1-for-10 reverse, Nov 28, 2018; 1-for-10 reverse, Apr 13, 2017; 1-for-10 reverse, Mar 17, 2017; 1-for-20 reverse, May 7, 2013; 1-for-20 reverse, May 1, 2013
- SEC CIK
- 1430306
- CUSIP
- 890260839
- ISIN
- US8902608392
- LEI
- 529900ACPKP9QW20GX48
- EIN
- 26-1434750
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Seth Lederman | Chief Executive Officer, Director | 31,007 |
| Thomas Englese | Chief Commercial Officer | 694 |
| Bradley Saenger | Chief Financial Officer | 2,154 |
| Siobhan Fogarty | Chief Technology Officer | 1 |
| Gregory M. Sullivan | Chief Medical Officer | 0 |
| Jessica Edgar Morris | Chief Operating Officer | 0 |
| Richard H. Bagger | Director | 1,000 |
| Carolyn E. Taylor | Director | 1,833 |
| Richard Newcomb Stillwell | Director | 5,000 |
| James Randolph Hunter Jr | Director | – |
| Adeoye Y. Olukotun | Director | 0 |
| Margaret Smith Bell | Director | 0 |
| David L. Grange | Director | – |
| James Treco | Director | 250 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Seth Lederman | $2.92M | $4.59M | $1.20M | $0 | – |
| FY2024 Seth Lederman | $1.81M | $1.06M | $886.72K | $0 | – |
| FY2023 Seth Lederman | $2.05M | $647.04K | $928.50K | $1 | – |
| FY2022 Seth Lederman | $4.58M | -$711.46K | $1.37M | $3 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 12, 2026, we had 142 full-time employees, of whom 29 hold M.D.”
Corporate history
Events identified from SEC filings